Theravance Biopharma, Inc.

TBPH

NASDAQ

Healthcare

Biotechnology

George Town, KY97 employeestheravance.com

$16.03

+0.19(1.2%)

52W $8.32 – $20.74

AI-generatedSource: 10-K filed Mar 22, 2026

Theravance Biopharma, Inc.

Revenue breakdown: Yupelri Monotherapy (46.4%), Collaborative Arrangement Revenue (36.6%), Licensing And Milestone (8.5%).

$825MMkt Cap

$107MRev TTM

$105MNI TTM

7.1xP/E TTM

Latest Earnings

10-K

FY FY2025Mar 22, 2026

Theravance Biopharma, Inc. reported strong FY 2025 financial performance, achieving net income of $105.9 million compared to a $56.4 million net loss in 2024, driven by one-time gains and milestone achievements. Total revenues reached $107.5 million, up 67% YoY from $64.4 million, primarily from Viatris collaboration revenue of $75.0 million (up 16%) reflecting YUPELRI net sales growth to $266.6 million...

Read full analysis View SEC Filing

What Changed Recently

Other EventMar 29, 2026

. Other Events ** On March 27, 2026, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, LLC and Theravance Biopharma Ireland Limited, subsidiaries of th

View filing →

Financial ResultsMar 18, 2026

and in Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 o

View filing →

ImpairmentMar 2, 2026

and Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, e

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Yupelri Monotherapy46.4%($354M)

Collaborative Arrangement Revenue36.6%($279M)

Licensing And Milestone8.5%($65M)

Milestone6.6%($50M)

License2%($15M)

Revenue by Geography

US81.1%($139M)

Europe18.9%($33M)

Company Profile

CIK0001583107

ISINKYG8807B1068

CUSIPG8807B106

Phone6508086000

AddressUgland House, George Town, KY1-1104, KY

SEC EDGAR